Journal
VACCINE
Volume 28, Issue 22, Pages 3767-3772Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.03.013
Keywords
Lentiviral vectors; NK and immunotherapy
Categories
Funding
- Manitoba Health Research Council, Manitoba Institute of Child Health
- Natural Sciences and Engineering Research Council [RGPIN/355727-2008]
- Canadian Institutes of Health Research (CIHR) [FRN 74754]
- Manitoba Health Research Council
- Ontario Ministry of Research and Innovation
- CIHR
- Burroughs Wellcome Fund
- Manitoba Blue Cross
- Manitoba Medical Service Foundation
Ask authors/readers for more resources
A balance of signals generated via stimulatory and inhibitory NK receptors determines both target cell specificity and the outcome of NK-target cell interactions. The feasibility of introducing naturally occurring or genetically engineered chimeric NM receptors at the effector cell level may prove useful in NK cell-based immunotherapies. Here, we utilized a previously established lentiviral transduction system to over-express a model NKR-P1B inhibitory receptor on primary mouse NK cells. These genetically engineered NM cells became more sensitive to inhibitory signals delivered by target cells expressing the cognate NKR-P1B ligand, Ocil/Clr-b. This study demonstrated the utility of lentiviral vectors as a means to stably manipulate the target cell specificity of primary NM cells. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available